Free US shipping on orders over Free US shipping over $500 · Ships next business day
Research Journal
Lab research notes, peer-reviewed findings, and practical protocols from our chemistry team. Deep dives into peptide purity, receptor pathways, handling best practices, and research methodology.
A lab-focused primer on Wegovy (semaglutide): mechanism, STEP trial outcomes, pharmacokinetics, analytical detection, and practical handling for research use only.
May 4, 2026
An in-depth, research-focused review of semaglutide (Ozempic): receptor pharmacology, pharmacokinetics, trial signals, experimental assays, analogue chemistry, and practical lab considerations for preclinical work.
May 4, 2026
A concise research-focused overview of MOTS‑c: sequence and mechanism, key preclinical findings, regulatory and anti‑doping status, safety unknowns, and procurement considerations for lab use.
May 3, 2026
A focused review of how peptide-based glow blends influence fibroblast activity, collagen production, and measurable endpoints for bench researchers — formulation, mechanisms, and assays for preclinical work.
May 1, 2026
A hands-on reference for laboratory use of oxytocin acetate: chemistry, receptor pharmacology, common assays, handling, control experiments, and sourcing considerations for preclinical research.
May 1, 2026
A research-focused guide to five commonly used peptides and small-molecule cofactors—GHK‑Cu, NAD+, BPC‑157, Kisspeptin‑10, and Sermorelin—covering mechanisms, common assays, handling, and experimental caveats.
May 1, 2026
A practical, research-focused guide to nicotinamide mononucleotide (NMN): what it is, how it fits into NAD+ biology, reported dose ranges in studies, handling and storage, and where to source NMN and basic supplies.
May 1, 2026
A lab-focused primer on GLOW Blend for researchers: composition context, mechanisms, in vitro and ex vivo assays, formulation and QC tips, and an example scratch assay protocol.
April 30, 2026
A large claims-based comparative study compared cardiovascular outcomes in nearly one million adults on tirzepatide, semaglutide, or other diabetes agents; both GLP-1–pathway agents showed measurable reductions in major events, with differe
April 29, 2026
The FDA will convene an advisory committee in July to consider easing compounding limits on seven peptides; researchers should track the regulatory steps, product-quality markers, and remaining data gaps for research-only use.
April 29, 2026
